160 Increasing gonadotrophin-releasing hormone dose at initiation of a 5-day CO-Synch protocol increases ovulatory response but not fertility in yearling beef heifers

Abstract

Heifers typically have a reduced ovulation rate following gonadotrophin-releasing hormone (GnRH) application at initiation of a CO-Synch + controlled internal drug release (CIDR) protocol. Thus, the objective of the present study was to determine whether increasing the dose of GnRH at initiation of a 5-day CO-Synch protocol in beef heifers would improve ovulation rate and therefore increase pregnancies per AI (P/AI). Angus yearling heifers (n=299) at five locations in Ohio (United States) were randomised to receive either 100µg (single; n=149) or 200µg (double; n=150) of gonadorelin acetate (Gonabreed, Parnell) at initiation of a 5-day CO-Synch. On Day −8, heifers received a new intravaginal progesterone-releasing device (1.38g of progesterone; CIDR, Zoetis) and either a single or double dose of GnRH as described above. Five days later (Day −3), devices were removed, 1000µg of cloprostenol sodium (Estroplan, Parnell) was administered, and an oestrous detection patch was applied (Estrotect, Rockway Inc.). Sixty hours after device removal, AI was performed concurrently with the administration of 100µg of GnRH. Pregnancy was determined using ultrasonography 35 days after AI. Ovaries from a subset of animals (n=178) were examined on Days −8 and −3 using ultrasonography to determine the presence of corpora lutea (CL) and the size of the largest follicle. Data were analysed using the GLIMMIX procedure of SAS ver. 9.4 (SAS Institute Inc.). Oestrous expression was similar (P=0.50) between heifers treated with a single (49.0%) or double (52.7%) dose of GnRH. Overall, P/AI was similar (P=0.35) between heifers receiving a single (43.6%; 65/149) or double (38.7%; 58/150) dose of GnRH at initiation of the protocol. However, increasing the dose of GnRH resulted in a greater (P=0.04) ovulation rate in heifers in the double-dose group (40.9%; 36/88) compared with those in the single-dose group (26.1%; 23/88). In addition, heifers with a CL at the time of treatment had reduced ovulatory response to GnRH treatment (16.0%) compared with heifers without a CL (53.7%; P=0.001); however, there was no treatment×CL presence interaction (P=0.69). Heifers that did not ovulate to the initial GnRH treatment had a greater (P=0.0008) diameter of the largest follicle on Day −3 compared with heifers that did ovulate (11.4±0.2 vs. 10.0±0.3). Furthermore, heifers that did ovulate after the initial GnRH had greater (P=0.04) P/AI (52.5%) than heifers that did not ovulate (40.2%), and heifers with a CL on Day −8 tended (P=0.07) to have greater P/AI (47.9%) than heifers without a CL (40.2%). In addition, heifers with a CL present on Day −3 had greater (P=0.04) P/AI (48.2%) than heifers without a CL (31.7%). In summary, increasing the dose of GnRH at initiation of a 5-day CO-Synch did not affect fertility to fixed-time AI but enhanced ovulation rate in beef heifers. Furthermore, heifers that did ovulate at initiation of the protocol or that had a CL at device insertion or removal had greater fertility to fixed-time AI. Thus, alternative strategies that maximise ovulation at initiation of the synchronisation protocol are needed.